AIVIS (CEO Daehong Lee), a company specializing in AI-driven digital pathology solutions, has received the Minister of Science and ICT Award. On December 30, 2025, AIVIS announced that it achieved outstanding results in the 2025 DATA-Global Data Company Overseas Expansion Support Program, hosted by the Ministry of Science and ICT and the Korea Data Agency. The company was highly evaluated for advancing its AI technology using German clinical data and for its localization efforts tailored to the European market. As part of the project, AIVIS collaborated with Katholisches Krankenhaus Hagen, Germany, to enhance its AI solution for quantitative analysis of tumor-infiltrating lymphocytes (TILs) based on histopathology slide data from head and neck cancer patients. Large-scale image data collected from real-world clinical environments were utilized for model training and validation, enabling the company to secure data quality and AI performance optimized for European healthcare settings. AIVIS also implemented a platform-independent AI pathology analysis architecture. The solution operates without dependency on specific hardware or scanners, allowing flexible integration across diverse hospital IT environments. In a third-party AI performance evaluation, the solution achieved an F1-score of 0.97, significantly exceeding the initial target performance. The company further strengthened its foundation for overseas market expansion by participating in multiple exhibitions and academic conferences, conducting on-site consultations with European buyers. Rather than focusing solely on short-term revenue, AIVIS prioritized clinical validation and mid- to long-term commercialization strategies. The validation outcomes from this project are expected to serve as key reference data for future European regulatory approvals. Looking ahead, AIVIS plans to initiate multi-center clinical studies across Europe, with Germany as a strategic hub. The company also aims to expand the range of cancer indications covered by its solutions while pursuing regulatory certifications. By combining hospital deployment models with a service-based revenue structure, AIVIS seeks to accelerate its growth into a global AI healthcare company. CEO Daehong Lee commented, “This award recognizes the real-world applicability of our solutions in European clinical settings,” adding, “We will continue to build clinical credibility and strengthen our competitiveness in the global precision diagnostics market.”